期刊
PURINERGIC SIGNALLING
卷 13, 期 1, 页码 75-87出版社
SPRINGER
DOI: 10.1007/s11302-016-9541-4
关键词
Spinal cord injury; Neuroprotection; Diadenosine; Tissue damage; Apoptosis; Excitotoxicity; Intracellular calcium; Secondary injury; Neuro-2a; Mouse model
资金
- Fundacion para la Investigacion Sanitaria de Castilla la Mancha (FISCAM) [PI-2010/19]
Reducing cell death during the secondary injury is a major priority in the development of a cure for traumatic spinal cord injury (SCI). One of the earliest processes that follow SCI is the excitotoxicity resulting from the massive release of excitotoxicity mediators, including ATP, which induce an excessive and/or prolonged activation of their receptors and a deregulation of the calcium homeostasis. Diadenosine tetraphosphate (Ap(4)A) is an endogenous purinergic agonist, present in both extracellular and intracellular fluids, with promising cytoprotective effects in different diseases including neurodegenerative processes. In a search for efficient neuroprotective strategies for SCI, we have tested the capability of Ap(4)A to reduce the excitotoxic death mediated by the ATP-induced deregulation of calcium homeostasis and its consequences on tissue preservation and functional recovery in a mouse model of moderate contusive SCI. Our analyses with the murine neural cell line Neuro2a demonstrate that treatment with Ap(4)A reduces ATP-dependent excitotoxic death by both lowering the intracellular calcium response and decreasing the expression of specific purinergic receptors. Follow-up analyses in a mouse model of contusive SCI showed that acute administration of Ap(4)A following SCI reduces tissue damage and improves motor function recovery. These results suggest that Ap(4)A cytoprotection results from a decrease of the purinergic tone preventing the effects of a massive release of ATP after SCI, probably together with a direct induction of anti-apoptotic and pro-survival pathways via activation of P2Y(2) proposed in previous studies. In conclusion, Ap(4)A may be a good candidate for an SCI therapy, particularly to reduce excitotoxicity in combination with other modulators and/or inhibitors of the excitotoxic process that are being tested.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据